StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Tivdak (tisotumab vedotin ADC by Year

Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — Worldwide revenues ($M) ($M)

QuarterlyAnnual

Pfizer Tivdak (tisotumab vedotin ADC: $147M in FY2025, up 12.2% from a year earlier.

Latest, FY2025
147
Period ended Dec 31, 2025
Change on a year earlier
+12.2%
131 in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below

Where the FY2025 figure comes from

“|| Tivdak | 147 | 131 | 13% | 13% | 140 | 126 | 11% | 7 | 5 | 59% | 59%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — Worldwide revenues ($M) ($M)Year on yearSource
FY2025Dec 31, 2025147+12.2%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024131+3,175.0%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2023Dec 31, 20234–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2022Dec 31, 20220–Form 10-K (filed 2025-02-27) ↗
FY2021Dec 31, 20210–Form 10-K (filed 2024-02-22) ↗

Breakdown

What makes up tivdak (tisotumab vedotin ADC

Cite this data

StockData. (2026). Pfizer Tivdak (tisotumab vedotin ADC ($M), annual FY2021–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/tivdak-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.